The Latest Breaking News from Pfizer

Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

LOS ANGELES — California schools reopened for the fall semester with loosened COVID-19 protocols and low student vaccination rates among younger children, presenting a new test for the trajectory of the pandemic as some experts expect another rise in cases when winter arrives.

Pfizer’s says its COVID-19 vaccine was 73% effective in protecting children younger than 5 as omicron spread in the spring

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 10 strange trades.

Pfizer Inc.’s COVID-19 vaccine was 73.2% effective against the disease in a trial of children 6 months through 4 years old, reinforcing results that led to the shot’s authorization in young kids in June.

Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.

Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.

Pfizer has asked U.S. regulators to authorize its combination COVID-19 vaccine that adds protection against the newest omicron relatives

Around 26m people across England eligible for autumn booster

The government plans to buy 2.9 million doses of Covid-19 vaccine from Pfizer for children aged from six months to four years.